TY - JOUR
T1 - Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients
AU - Francica, Giampiero
AU - Saviano, Antonio
AU - De Sio, Ilario
AU - De Matthaeis, Nicoletta
AU - Brunello, Franco
AU - Cantamessa, Alessandro
AU - Giorgio, Antonio
AU - Scognamiglio, Umberto
AU - Fornari, Fabio
AU - Giangregorio, Francesco
AU - Piscaglia, Fabio
AU - Gualandi, Silvia
AU - Caturelli, Eugenio
AU - Roselli, Paola
AU - Rapaccini, Gian Ludovico
AU - Pompili, Maurizio
PY - 2012
Y1 - 2012
N2 - BACKGROUND: Radiofrequency Ablation is the most widely performed percutaneous treatment for Hepatocellular Carcinoma. This multicentre study was aimed at assessing the complication, overall survival and disease-free survival rates in cirrhotic patients with single Hepatocellular Carcinoma nodule ≤3cm undergoing Radiofrequency Ablation. METHODS: Data of 365 patients (59% males; mean age 67±8 years), Child-Pugh A/B, with single Hepatocellular Carcinoma nodule ≤3cm (tumours >2-3cm=127/236), showing complete necrosis after Radiofrequency Ablation between 1998 and 2010 in 7 Italian Centers were retrospectively reviewed. Complication, overall survival and disease-free survival rates were analyzed as main clinical end-points. RESULTS: Major complications were observed in 8 patients (2.2%) and minor complications in 23 patients (6.3%). The 3-, and 5-year overall survival rates were 80% and 64%. One hundred and seven patients (29.5%) died, being 41 deaths (38.3%) Hepatocellular Carcinoma-related. At multivariate analysis only age (p=0.04; OR 2.29), ascites (p<0.001; OR 3.74) and Child-Pugh class ≥B8 (p=0.003; OR 2.42) were confirmed as independent predictors for overall survival. The disease-free survival rates at 3- and 5-year were 50%, and 41.8%. CONCLUSIONS: Radiofrequency Ablation is an effective and safe tool for the treatment of single Hepatocellular Carcinoma ≤3cm providing excellent 5-year overall survival and disease-free survival rates. Patient's age and liver status appeared as main determinants of outcome.
AB - BACKGROUND: Radiofrequency Ablation is the most widely performed percutaneous treatment for Hepatocellular Carcinoma. This multicentre study was aimed at assessing the complication, overall survival and disease-free survival rates in cirrhotic patients with single Hepatocellular Carcinoma nodule ≤3cm undergoing Radiofrequency Ablation. METHODS: Data of 365 patients (59% males; mean age 67±8 years), Child-Pugh A/B, with single Hepatocellular Carcinoma nodule ≤3cm (tumours >2-3cm=127/236), showing complete necrosis after Radiofrequency Ablation between 1998 and 2010 in 7 Italian Centers were retrospectively reviewed. Complication, overall survival and disease-free survival rates were analyzed as main clinical end-points. RESULTS: Major complications were observed in 8 patients (2.2%) and minor complications in 23 patients (6.3%). The 3-, and 5-year overall survival rates were 80% and 64%. One hundred and seven patients (29.5%) died, being 41 deaths (38.3%) Hepatocellular Carcinoma-related. At multivariate analysis only age (p=0.04; OR 2.29), ascites (p<0.001; OR 3.74) and Child-Pugh class ≥B8 (p=0.003; OR 2.42) were confirmed as independent predictors for overall survival. The disease-free survival rates at 3- and 5-year were 50%, and 41.8%. CONCLUSIONS: Radiofrequency Ablation is an effective and safe tool for the treatment of single Hepatocellular Carcinoma ≤3cm providing excellent 5-year overall survival and disease-free survival rates. Patient's age and liver status appeared as main determinants of outcome.
KW - cirrhosis
KW - liver tumor ablation
KW - cirrhosis
KW - liver tumor ablation
UR - http://hdl.handle.net/10807/39945
U2 - 10.1016/j.dld.2012.10.022
DO - 10.1016/j.dld.2012.10.022
M3 - Article
SN - 1590-8658
VL - 45
SP - 336
EP - 341
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
ER -